1108 results about "Neurological disorder" patented technology

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.

Disclosed herein are methods for treating impairment of a limb in a subject. Particular methods comprise applying a therapeutically effective amount of an electrical stimulus to dorsal roots, dorsal rootlets, or dorsal root ganglia, of sensory neurons innervating the limb of the subject, wherein the impairment is a motor impairment and / or a proprioception impairment due to neurological disorder or injury, the electrical stimulus is applied with one or more electrodes controlled by a neurostimulator, and the one or more electrodes are implanted in the epidural space at the dorsolateral aspect of the spinal cord and proximate to the dorsal roots or dorsal rootlets of the sensory neurons innervating the limb of the subject, or the one or more electrodes are implanted proximate to dorsal root ganglia of sensory neurons innervating the limb of the subject.

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

Disclosed herein are apparatuses and methods for treating neurological disorders by electro-stimulation. The apparatus (10) for treating neurological disorders includes at least one electrode (12) implantable in the brain of a patient, and a processing and stimulation device (14) connected to the at least one electrode (12). The processing and stimulation device (14) may include a stimulation module (16) configured to generate a stimulation signal to be sent to the at least one electrode (12), and an acquisition module (20) that measures cerebral activity coming from the brain of the patient. The acquisition module (20) may have a front-end block (27) configured to amplify the potential difference of its input signals (V1a, V2a) and to filter a stimulus artifact and may include a multi-stage fully-differential switched capacitor circuit (e.g., an integrated circuit) configured for discrete-time signal processing.

Systems and methods for computer modeling in medicine. A sort of period table of medical models is described for personalized diagnostics, prognostics and therapeutics, including at least 80 major categories of medical models. Generative artificial intelligence and geometric deep learning techniques, and algorithms including 2D and 3D graph machine learning and GenAI algorithms, are described, tailored and applied to diagnostic disease description, prognostic prediction and therapeutic development and management, including generation of novel synthetic drugs. The AI and machine learning techniques and algorithms are applied to understand each individual's genetic, RNA and protein anomalies that represent the source of many unique patient diseases. AI-enabled software agents assist physicians and researchers in building patient medical models. Several personalized medicine applications of individualized medical modeling include cardiovascular disease, cancer, neurological disorders, immune system disorders and genetic diseases.

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

The present invention relates to: a sustained-release injectable composition for treating or preventing neurological disorders; and a method for preparing same. The sustained-release injectable composition uses microparticles containing cannabidiol and continuously releases the cannabidiol for at least one month, and thus can be effective in treating or preventing neurological disorders. In addition, the sustained-release injectable composition includes cannabidiol, which is non-toxic and can be used continuously for a long time due to the absence of side effects from long-term use, and thus can exhibit a therapeutic or prophylactic effect on neurological disorder patients for at least one month through a single injection. Therefore, the sustained-release injectable composition can greatly improve the convenience of administration.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for inhibiting CYP26B1. Aspects of the present disclosure also include methods of using the compounds to treat diseases or disorders, including, but not limited to, skin disorders, cancer, neurological disorders, heterotopic ossification (HO), fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas, and diseases or disorders of the eye, including meibomian gland dysfunction and dry eye disease.

Caloric stimulation and pressure stimulation can be applied to the ear for treatment of neurological disorders, such as migraine, pain, and headache. Heat can be applied first to increase the sensitivity of the mechanoreceptors in the ear. The pressure can be applied after heating to produce a stronger neurological response than would occur without the heating. In some cases, cooling can be used. Valves can be used to direct fluid flow to a right ear, a left ear, or both. Valves can be used to transition the system between an irrigation or caloric mode and a pressure mode. Green eyewear can be used for therapeutic relief.

The invention discloses a motor cortex excitability evaluation method based on threshold tracking magnetic stimulation, and relates to the technical field of biomedical engineering. The motor cortex excitability assessment method based on threshold tracking magnetic stimulation comprises the following steps: performing electrical stimulation on median nerves of a wrist of a subject, recording on an abductor politics brevis (APB), recording a stimuli-response curve, determining a stimuli-response (SR) curve of cortex stimulation by increasing the magnetic stimulation intensity to the following level, and determining the stimuli-response (SR) curve of cortex stimulation according to the stimuli-response (SR) curve. And calculating statistical parameters of the average value and the standard deviation of the excitability threshold values, and judging the dynamic trend of cortical excitability. According to the method, the stimulation-reaction curve of cortex stimulation is determined by improving the magnetic stimulation intensity to the following level, the central movement conduction time is calculated through the F-wave method based on the stimulation-reaction curve, initial stimulation and threshold determination are completed, subsequent threshold tracking is carried out on the technology, and the accuracy and the reliability of the system are improved. And an efficient and accurate brain motor cortex function detection means is provided for diagnosis of nervous system diseases.

The present invention relates to the fields of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of the central nervous system. The disclosed methods and compositions involve localised administration into such organs of an effector component that targets an intracellular biological target, in combination with a saponin component that enhances effective uptake of the effector component into the cells and / or that enhances effective routing of the effector component inside the cells where the biological target is present. For example, the effector component can be an oligonucleotide therapeutic that is targeting a gene product associated with the disorder of the CNS. Due to cellular uptake-stimulating and / or endosomal escape enhancing effects of the saponin component, the presented herein neuropharmaceutical compositions for the localised administration into the CNS can be formulated with lower concentrations of the effector component and / or at lower volumes, which confers safety-benefits to the neurons and to the comfort of the patient.

The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as depression, anxiety, and trauma- and stressor-related disorders, comprising the indolizines having the structures disclosed herein.

The disclosure provides a compound of Formula Ib or Formula IIb, or a hydrate thereof, a pharmaceutical composition such as a spray-dried pharmaceutical composition comprising the compound of Formula Ib or Formula IIb, or a hydrate thereof, as well as methods of preparation thereof, and use thereof in the treatment and / or prevention of one or more of the following dysfunctions or disorders: a sexual dysfunction, erectile dysfunction, ejaculatory dysfunction, hypoactive sexual desire disorder, psychiatric disorder, neurological disorder.

Provided are compositions and methods of using compositions including probiotics for treatment and prevention of a variety of pain disorders, neurological disorders, and / or physiological disorders. The compositions include one or more bacterium capable of producing γ-Aminobutyric acid (GABA). The bacterium is selected from Bifidobacterium adolescentis, Limosilactobacillus reuteri, and Lactiplantibacillus plantarum.

The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.

The present application relates to compounds of formula (I), and their pharmaceutical compositions / preparations. This application further relates to methods of treating Rett syndrome and / or one or more symptoms associated with Rett syndrome, FOXG1 syndrome and / or one or more symptoms associated with FOXG1 syndrome, CDKL5 deficiency disorder (CDD) and / or one or more symptoms associated with CDD, or CHD8-related neurodevelopmental disorder (CHD8-NDD) and / or one or more symptoms associated with CHD8-NDD, chronic heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), or heart failure with mid-range ejection fraction (HFmrEF).

Described herein are compositions that comprise Bumetanide Dibenzylamide for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, the present disclosure relates to methods and compositions for treating neurological disorders by administering agents that disrupt hypersynchronized neuronal activity without diminishing neuronal excitability. These compositions are useful for seizure disorders, epilepsy, and related indications.

Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and / or compositions described herein.

Disclosed are ready to use non-aqueous solutions of lamotrigine. The lamotrigine is dissolved in a solvent, wherein the solvent comprises propylene glycol and optionally at least one co-solvent, and wherein if water is present in the ready to use non-aqueous solution, the water is not at least one co-solvent. Also disclosed are methods for treating a neurological disorder or a mental disorder by administering the ready to use non-aqueous solutions of lamotrigine, processes for preparing ready to use non-aqueous solutions of lamotrigine, and kits containing lamotrigine to prepare ready to use non-aqueous solutions of lamotrigine.

Methods and systems useful for detecting neurological disorders and for measuring general cognitive performance, in particular by measuring eye movements and / or pupil diameter during eye-movement tasks.

Described herein are shock wave catheters and methods of use thereof for delivering an active agent of a drug to the CNS via a body lumen or cavity, such as sinonasal cavity, which can bypass the blood-brain barrier (BBB). The catheters described herein can be advanced through an intranasal passage to the nasal cavity such that at least a portion of the enclosure is disposed in the nasal cavity. The enclosure can be coated with a drug coating. The method can include filling the enclosure with a conductive fluid. At least one shock wave can be generated at a shock wave emitter of the catheter disposed within the enclosure. The at least one shock wave can cause a therapeutically effective amount of the active agent of the drug coating to be delivered to the CNS via tissue of the nasal cavity, in turn, treating central nervous system diseases.

The present embodiments relate generally to therapeutic techniques and more particularly to effective treatment of neurological disorders using noninvasive methods and apparatuses. Some embodiments relate to more effective vibrotactile stimulation, i.e., stronger physiological effects with less vibration power / amplitude, by means of a vibrotactile mechanical stimulator (tactor).

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

Disclosed herein novel dopamine D3 receptor selective antagonists / partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic tools. Also disclosed are methods of making the compounds.

Described herein are methods relating to the treatment of certain diseases with an agonist of Mfsd2A, and the treatment of certain other diseases with an inhibitor of Mfsd2A.